{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-132980","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2021-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.686985+00:00","generated_at":"2026-06-28T15:15:02.639235+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Entrada Therapeutics files amended charter and bylaws in connection with IPO","bullets":["Authorizes 150M shares of common stock and 10M shares of undesignated preferred stock.","Bylaws eliminate stockholder action by written consent, set procedures for proposals and nominations.","Changes previously disclosed in S-1; effective upon IPO consummation on November 2, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-132980","json":"https://secwatch.observer/filing/0001104659-21-132980.json","markdown":"https://secwatch.observer/filing/0001104659-21-132980.md","text":"https://secwatch.observer/filing/0001104659-21-132980.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465921132980/0001104659-21-132980-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465921132980/tm2131671d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:15:02.639235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}